<DOC>
	<DOCNO>NCT00002532</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient relapsed refractory acute lymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Relapsed Refractory Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxic effect feasibility high-dose cytarabine idarubicin patient refractory relapse acute lymphocytic leukemia ( ALL ) complete remission ( CR ) less 18 month . II . Determine response patient ALL first relapse CR 18 month treat 2-phase re-induction regimen comprise prednisolone , vindesine , daunorubicin , asparaginase , intrathecal ( IT ) cytarabine , IT dexamethasone , IT methotrexate follow prednisolone , ifosfamide , high-dose methotrexate , leucovorin calcium , etoposide , cytarabine ( dose-escalation study etoposide cytarabine ) . III . Compare effectiveness 2 regimen administer patient regimen administer historic control ( protocol GER-ALL-REZ- 01/88 ) . OUTLINE : This dose-escalation , multicenter study . Patients stratify center , duration complete remission ( CR ) ( le 18 month vs 18 month ) , refractory disease ( yes v ) . Patients refractory relapse disease CR le 18 month treat Regimen A . Patients first relapse CR 18 month treat Regimen B . Regimen A : Patients receive idarubicin IV 30 minute follow cytarabine IV 3 hour day 1-3 filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 5 continue blood count recover . Regimen B ( 2-phase reinduction ) : Patients receive oral prednisolone day 1-21 ; vindesine IV daunorubicin IV day 1 , 8 , 15 ; asparaginase IV day 7 , 8 , 14 , 15 ; methotrexate intrathecally ( IT ) , cytarabine IT , dexamethasone IT day 1 8 . When blood count recover , patient receive oral prednisolone ifosfamide IV 1 hour day 1-4 ; high-dose methotrexate IV continuously day 1 follow standard leucovorin calcium rescue ; etoposide IV 1 hour follow least 8 hour later cytarabine IV 3 hour day 3 4 ; G-CSF SC begin day 6 continue blood count recover . Cohorts 6 patient receive escalate dos etoposide cytarabine maximum tolerate dose determine . PROJECTED ACCRUAL : Approximately 60 patient ( 30 per regimen ) accrue study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis refractory relapse acute lymphocytic leukemia No isolate extramedullary relapse ( e.g. , testicular , CNS ) Combined extramedullary bone marrow relapse allow No uncontrolled , severe leukemic complication , e.g . : Pneumonia hypoxia Shock Cardiac failure Hemorrhage No refractoriness platelet transfusion No unaspirable pleural effusion ascites patient first relapse PATIENT CHARACTERISTICS : Age : 15 65 Performance status : Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : See Disease Characteristics No uncontrolled bleed Hepatic : No severe liver disease Renal : Creatinine clearance least 60 mL/min patient first relapse complete remission 18 month Cardiovascular : See Disease Characteristics No severe cardiac disease ( e.g. , congestive heart failure , myocardial infarction within past 6 month , severe arrhythmia ) Pulmonary : See Disease Characteristics No severe pulmonary disease would preclude aggressive chemotherapy Other : No hypersensitivity E. coli proteins No severe neurologic disease would preclude aggressive chemotherapy No severe psychiatric disease condition would preclude study PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2002</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
</DOC>